Please login to the form below

Not currently logged in
Email:
Password:

BCMA-targeting therapy

This page shows the latest BCMA-targeting therapy news and features for those working in and with pharma, biotech and healthcare.

BMS and bluebird bio gain FDA approval for multiple myeloma therapy

BMS and bluebird bio gain FDA approval for multiple myeloma therapy

Abecma is a CAR T cell therapy approved for pre-treated myeloma patients. ... The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb (BMS) and bluebird bio’s BCMA-targeting CAR T cell therapy Abecma – previously known as ide-cel

Latest news

  • bluebird bio to separate oncology and rare diseases units bluebird bio to separate oncology and rare diseases units

    Oncology Newco will assume responsibility for a number of bluebird bio’s current oncology assets, including its investigational BCMA-targeting CAR T therapy idecabtagene vicleucel (ide-cel), which is currently being ... In addition, Oncology Newco will

  • Bluebird bio leans on pipeline and Zynteglo launch as revenues fall Bluebird bio leans on pipeline and Zynteglo launch as revenues fall

    Bluebird is in partnership with BMS for a BCMA-targeting cell therapy – bb2121 or ide-cel – which recently demonstrated positive top-line results in multiple myeloma. ... Aside from the mixed figures, bluebird is looking forward and focusing on the

  • FDA begins speedy review of BMS’ CAR-T liso-cel FDA begins speedy review of BMS’ CAR-T liso-cel

    or whose disease has relapsed,” said Stanley Frankel, senior vice president, cellular therapy development, BMS. ... In addition to liso-cel, BMS has another CAR-T therapy in the pipeline – its bluebird bio-partnered BCMA-targeting therapy bb2121 for

  • J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data

    Both candidates are being studied in multiple myeloma. Johnson and Johnson and Bristol-Myers Squibb/Bluebird bio have both revealed data from their respective BCMA-targeting CAR-T therapies in multiple ... BMS/Bluebird also had their own CAR-T data in

  • GSK preps filings for BCMA-targeting multiple myeloma drug GSK preps filings for BCMA-targeting multiple myeloma drug

    GSK2857916 is one of a slew of BCMA-targeting therapies coming through the biopharma industry pipeline, jostling for position with a CAR-T therapy from Celgene and Bluebird Bio called bb2121 ... It is the most advanced BCMA-targeting ADC in development,

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...